Sangamo Therapeutics, Inc (SGMOQ): Total Assets
$59.74M
As of 2025-12-31
$59.97M
As of 2026-03-31
-52.6%
3-year compound annual growth
-42.4%
5-year compound annual growth
-12.1%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.74M | -41.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $101.64M | -38.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $165.32M | -70.6% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $562.51M | -22.1% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $721.92M | -23.1% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $938.55M | +47.2% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $637.52M | +8.0% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $590.39M | +105.9% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $286.74M | +81.6% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $157.89M | -27.3% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $217.24M | -10.7% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $243.21M | +72.7% | 2016-02-18, Balance as of period end |
| 2013-12-31 | $140.84M | +70.6% | 2015-02-25, Balance as of period end |
| 2012-12-31 | $82.53M | -5.5% | 2014-02-24, Balance as of period end |
| 2011-12-31 | $87.34M | +38.6% | 2013-02-26, Balance as of period end |
| 2010-12-31 | $63.00M | n/a | 2012-02-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗